The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Music
  • Construction
  • Financial
  • Manufacturing

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
  • Snap-a-Box Brings Texas' First Robot-Cooked Chinese Takeout to Katy–Fulshear
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • James D. Harding Promoted to Century Fasteners Corp. – Managing Director
  • Finland's New Gambling Watchdog Handed Sweeping Powers to Revoke Licenses and Block Illegal Casino Sites
  • Powering the AI, Defense and Aerospace Future with Energy Infrastructure and Digital Asset Strength: KULR Technology Group, Inc. $KULR
  • $10 Price Target in Think Equity Report Supported by Inventory Financing Floorplan Boot to $60 Million for 2026 Sales Growth in Pre-Owned Boats: $OTH
  • Poolvillas Expands Local Presence on the Costa Blanca with New Offices in Moraira and Denia – Over 30 Years of Expertise Now Even Closer to Guests

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • MILBERT.ai Brings Real Time Session Defense to Google Workspace and Google Cloud
  • Appliance Outlet Caps Off a Record-Setting 2025 Nationwide, Gears Up for Even Greater Growth in 2026
  • Perry County Real Estate Agency Partners with Internet Marketing Company
  • Philadelphia HVAC Companies Were Not Created Equal
  • Home Prices Just Hit 5X Median Income — So Americans Are Buying Businesses Instead of Houses
  • Briggs Auction's Jan. 30 online Fine Estates Auction features artworks by Hans Hoffman, Hans Coper, Lucie Rie, Loet Vanderveen
  • Peak Exteriors LLC to Open First Office in East Berlin in 2026
  • CCHR White Paper Urges Government Crackdown on Troubled Teen and For-Profit Psychiatric Facilities
  • MoMojo Records signs Billy Thompson
  • Still Searching for the Perfect Valentine's Gift? Lick Personal Oils Offers Romantic, Experience-Driven Alternatives to Traditional Presents
  • Jaeigh Gallagher Records: Redefining Independent Music and Global Pop Culture
  • Boston Industrial Solutions' BPA Certified BX Series Raises the Bar for Pad Printing Inks
  • Boston Corporate Coach™ Sets Global Standard for Executive Chauffeur Services Across 680 Cities
  • UK Financial Ltd Announces CoinMarketCap Supply Verification And Market Positioning Review For Regulated Security Tokens SMPRA And SMCAT
  • Sharpe Automotive Redefines Local Car Care with "Transparency-First" Service Model in Santee
  • L-Tron to Exhibit at PACK EXPO East Packaging and Processing Conference in Philadelphia, PA
  • Reputation Management Services Expanded
  • Secondesk Launches Powerful AI Tutor That Speaks 20+ Languages
  • Automation, innovation in healthcare processes featured at international conference in Atlanta
  • A High-Velocity Growth Story Emerges in Marine and Luxury Markets

Popular on PennZone

  • Neurosurgeon Chengyuan Wu, MD, MSBmE, Joins the Actuated Medical Advisory Board - 223
  • CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
  • Stockwell Elastomerics expands micro molding capabilities
  • Price Improvement on Luxurious Lāna'i Townhome with Stunning Ocean Views
  • Together We Dance Foundation Announces Transformational Support from NAC Have a Heart Foundation
  • Lacy Hendricks Earns Prestigious MPM® Designation from NARPM®
  • Harry Hayman Celebrates Years of WHYY Coverage, Partnership & Shared Commitment to Philadelphia
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
  • Robert DeMaio, Phinge Founder & CEO, Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
  • Phinge Founder & CEO Robert DeMaio Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes

Similar on PennZone

  • SNS Research Launches SNS Market Intelligence Platform for visual market intelligence for pharma
  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
  • AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us